WHO ICTRP trial
Comparing two schedules of rituximab maintenance in rituximab-responding…
EUCTR2004-002859-13-IT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2004-002859-13-IT |
|---|---|
| Public title | Comparing two schedules of rituximab maintenance in rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma: A randomized phase III trial |
| Scientific title | Comparing two schedules of rituximab maintenance in rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma: A randomized phase III trial |
| Primary sponsor | SIAK |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma MedDRA version: 6.1 Level: HLT Classification code 10025634 |
| Interventions | Trade Name: MABTHERA*IV 1 FL 500 MG 50ML Product Name: NA Product Code: NA Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration… |
| Registration date | Jul 13, 2005 |
| Secondary IDs | SAKK 35/03 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: